Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (VRCA) will present a new pooled analysis of YCANTH Phase 3 trials showing faster complete clearance of molluscum contagiosum. The post-hoc analysis of CAMP-1 and CAMP-2 found an approximately 4-fold faster rate of complete clearance versus vehicle, regardless of disease duration. Estimated cumulative complete clearance by Day 84 was 60.1% versus 19.9%.
The YCANTH poster will appear at Fall Clinical on October 8–11, 2026, and PeDRA on October 15–17, 2026. Fall Clinical will also feature an encore exploratory Phase 2 analysis of VP-315 examining potential effects on untreated basal cell carcinoma tumors after injections into separate target tumors.
Verrica Pharmaceuticals (VRCA) will present new YCANTH and VP-315 clinical data at the Las Vegas Dermatology Seminar and Maui Derm NP+PA Fall 2026 conferences in September 2026.
A post-hoc pooled analysis of two Phase 3 trials in molluscum contagiosum found YCANTH achieved complete clearance at Day 84 in 48.9% of patients with disease ≤12 months versus 16.7% on vehicle, and in 58.8% of patients with disease >12 months versus 5.0% on vehicle (all p<0.0001). Median lesion-count reduction with YCANTH was 100% in both duration groups, compared with 47.9% and 50.9% for vehicle. An encore VP-315 Phase 2 analysis in basal cell carcinoma observed mean tumor-size reduction in 14 untreated non-target lesions and complete histological clearance in 3 of these lesions, suggesting a potential abscopal-like immune effect.
Verrica Pharmaceuticals (VRCA) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 1:00 p.m. ET in New York, NY.
President and CEO Jayson Rieger, PhD, MBA, is scheduled to speak. A live webcast will be available via a provided link and in the Investors/Presentations & Events section of Verrica’s website, with a replay accessible for 90 days after the event.
Verrica develops and commercializes treatments for dermatological diseases, including skin cancers. Its FDA-approved product YCANTH (VP-102) treats molluscum contagiosum in patients aged two years and older and is also being developed for common warts. Verrica also holds a worldwide license with Lytix Biopharma ASA for VP-315 (ruxotemitide) for non-melanoma skin cancers.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported completion of enrollment in COVE-2, the first pivotal Phase 3 trial of YCANTH (VP-102) for treating common warts, following an interim per-protocol power analysis that recommended no additional subjects. COVE-3, the second pivotal Phase 3 trial, has surpassed 50% of its current target enrollment.
According to Verrica, topline data from COVE-2 are expected in Q1 2027, with remaining Phase 3 readouts, including COVE-3, anticipated by mid-2027. The global program includes COVE-2 and COVE-3, a long-term follow‑up study (COVE-4), and a pharmacokinetics study (COVE-5). Torii Pharmaceutical, Verrica’s Japanese development partner, will fund the first $40 million of Phase 3 costs, representing about 90% of the current trial budget, within a 50/50 cost-sharing structure. Verrica highlights common warts as a major unmet need, affecting an estimated 22 million U.S. patients and lacking any FDA-approved prescription drug therapies.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q2 2026 total revenue of $5.9 million versus $12.7 million a year earlier, including U.S. YCANTH® net product revenue of $5.1 million, up 18.7% sequentially and 12.3% year-over-year. Dispensed YCANTH applicator units reached 19,626, rising 28.3% quarter-over-quarter and 46.1% year-over-year.
License and collaboration revenue declined to $0.8 million from $8.2 million due to the absence of a prior $8.0 million milestone. Net loss was $13.2 million versus net income of $0.2 million. Verrica entered a new credit facility of up to $27.5 million, which it believes could extend its cash runway into 2028, and it continues a global Phase 3 common warts program with topline data expected in mid-2027, while advancing Phase 3 readiness for VP-315 in basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) closed a new credit facility of up to $27.5 million in non-dilutive growth capital with an entity controlled by Chairman and largest shareholder Paul B. Manning. The facility is intended to support YCANTH commercialization, the global Phase 3 common warts program and general corporate purposes.
Verrica may access $12.5 million immediately, with an additional $15.0 million available upon achieving specified revenue, growth and operational milestones. Borrowings accrue interest at one-month SOFR + 8.00% (with a 4.50% SOFR floor), are payable in kind, and mature on December 31, 2030, with potential for no scheduled principal or interest payments until maturity, subject to conditions. The facility is secured by substantially all assets of Verrica and certain subsidiaries. According to Verrica, full availability could extend its cash runway into 2028 and fund Phase 3 data readouts for YCANTH in common warts expected by mid-2027.
Verrica Pharmaceuticals (Nasdaq: VRCA) will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss second quarter 2026 financial results and provide a corporate update. Participants can join via domestic dial-in 1-800-225-9448, international 1-203-518-9708, using conference ID: VERRICA, or through the investor relations section of the company website.
A replay of the webcast will be archived on Verrica’s website for 90 days. Verrica develops and commercializes treatments for dermatological diseases, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, and is developing YCANTH for common warts and VP-315 under license from Lytix Biopharma for non-melanoma skin cancers.
Verrica Pharmaceuticals (Nasdaq: VRCA) has entered into an exclusive distribution, marketing and supply agreement with Medomie Pharma, granting Medomie rights to seek regulatory approval for and distribute YCANTH for molluscum contagiosum in Israel. Verrica will manufacture YCANTH, supply commercial product to Medomie, and receive 60% of the net selling price of YCANTH sold in Israel, plus eligibility for up to $8.2 million in regulatory and commercial milestone payments.
YCANTH, a proprietary cantharidin-based, single-use applicator treatment, is the first and only FDA-approved, healthcare professional-administered therapy for molluscum in patients aged two years and older, supported by Phase 3 trials in about 500 patients and broad U.S. insurance coverage.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported dosing the first U.S. patient in COVE-3, the second pivotal Phase 3 trial of YCANTH (VP-102) for common warts. Torii Pharmaceutical recently dosed the first Japanese patient. A prior Phase 2 trial showed 51% complete clearance at Day 84. Torii will fund the first $40 million of Phase 3 costs, about 90% of the current budget, under a 50/50 cost-sharing agreement.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that President and CEO Jayson Rieger will present at the Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026, at 11:05 a.m. ET, with a live and replay webcast available via Verrica’s investor website.